Photo of Nikhil C. Munshi taken from www.multiplemyeloma.org
Apr 15, 2024, 12:53
Nikhil C. Munshi: Getting MRD as an endpoint was a great partnership between academia and industry and patient organization
Nikhil C. Munshi, Associate Director of the Jerome Lipper Multiple Myeloma Center at the Dana-Farber Cancer Institute, shared a post on X:
“Getting Minimal Residual Disease (MRD) as an endpoint was a great partnership between academia and industry and patient organization. A model to follow. Patients are three winner.”
Source: Nikhil C. Munshi/X
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 2, 2025, 11:39
Aug 2, 2025, 11:32
Aug 2, 2025, 11:26
Aug 2, 2025, 11:21